Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Phosphate Sandoz effervescent tablets
090502100BPAAAA
|
Proprietary compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 6,294 |
|
Sodium dihydrogen phosphate anhydrous 1.936g efferv tab
090502100AAAAAA
|
Generic compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 653 |
|
Phosphate 0.98mmol/ml / Sodium 0.78mmol/ml oral solution
090502100AAAMAM
|
Generic compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 90 |
|
K-Phos Neutral tablets
090502100BPBCA0
|
Proprietary compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 82 |
|
Phosphate 1mmol/ml oral solution
090502100AAAQAQ
|
Generic compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 4 |
|
Phosphate 0.98mmol/ml / Sodium 0.78mmol/ml oral suspension
090502100AAARAR
|
Generic compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 1 |
|
Phosphate Phebra effervescent tablets
090502100BPBDAA
|
Proprietary compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | 1 |
|
AadPhos effervescent tablets
090502100BPBEAA
|
Proprietary compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | No data available |
|
K-Phos No.2 tablets
090502100BPBBA0
|
Proprietary compound preparation BNF 0905021 | Other phosphate supplement preparations | Nutrition and Blood | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.